ABEONA THERAPEUTICS INC. (ABEO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 9M 18M 27M Q1 '11: 529K Q2 '11: 574K Q1 '12: 3.5M Q2 '12: 4.1M Q3 '12: 3.9M Q4 '12: 4.4M Q1 '13: 3.8M Q2 '13: 3.6M Q3 '13: 2.9M Q4 '13: 2M Q1 '14: 1M Q2 '14: 806K Q3 '14: 853K Q4 '14: 925K Q1 '15: 975K Q2 '15: 1M Q3 '15: 1.1M Q4 '15: 1M Q1 '16: 1M Q2 '16: 949K Q3 '16: 848K Q4 '16: 889K Q1 '17: 840K Q2 '17: 843K Q3 '17: 878K Q4 '17: 837K Q1 '18: 1.2M Q2 '18: 1.2M Q3 '18: 2.7M Q4 '18: 3M Q1 '19: 2.5M Q2 '19: 2.2M Q4 '22: 1.4M Q1 '23: 1.1M Q2 '23: 3.6M Q3 '23: 3.6M Q4 '23: 3.5M Q4 '25: 5.8M Q1 '26: 14.5M Q2 '26: 25.5M Q3 '12 Q4 '13 Q1 '15 Q2 '16 Q3 '17 Q4 '18 Q2 '23 Q2 '26

Gross Profit TTM

0 6M 12M 18M Q2 '26: 17.1M Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -24.3M Q4 '16: -23.9M Q1 '17: -23M Q2 '17: -24.7M Q3 '17: -24.9M Q4 '17: -27.8M Q1 '18: -33.2M Q2 '18: -37.4M Q3 '18: -48.9M Q4 '18: -58.2M Q1 '19: -66.5M Q2 '19: -78M Q3 '19: -78.7M Q4 '19: -77.1M Q1 '20: -106.2M Q2 '20: -94.8M Q3 '20: -83.4M Q4 '20: -81.4M Q1 '21: -47.8M Q2 '21: -49M Q3 '21: -57.7M Q4 '21: -89.8M Q1 '22: -95.8M Q2 '22: -90.1M Q3 '22: -84.6M Q4 '22: -50.9M Q1 '23: -42.4M Q2 '23: -44.9M Q3 '23: -46.9M Q4 '23: -47.1M Q1 '24: -49.4M Q2 '24: -56.7M Q3 '24: -60.7M Q4 '24: -64.2M Q1 '25: -69.6M Q2 '25: -74.5M Q3 '25: -83.2M Q4 '25: -89.4M Q1 '26: -92.8M Q2 '26: -83.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-120M -80M -40M 0 40M 80M 120M Q3 '16: -17.2M Q4 '16: -21.9M Q1 '17: -21.6M Q2 '17: -23.2M Q3 '17: -25.9M Q4 '17: -27.3M Q1 '18: -32.6M Q2 '18: -36.6M Q3 '18: -47.6M Q4 '18: -56.7M Q1 '19: -64.7M Q2 '19: -76.4M Q3 '19: -77.3M Q4 '19: -76.3M Q1 '20: -105.9M Q2 '20: -95M Q3 '20: -84.8M Q4 '20: -84.2M Q1 '21: -52.1M Q2 '21: -54.3M Q3 '21: -54.1M Q4 '21: -84.9M Q1 '22: -91M Q2 '22: -79.9M Q3 '22: -79.3M Q4 '22: -39.7M Q1 '23: -26.8M Q2 '23: -39.3M Q3 '23: -44.7M Q4 '23: -54.2M Q1 '24: -76.7M Q2 '24: -52.6M Q3 '24: -71M Q4 '24: -63.7M Q1 '25: -44.2M Q2 '25: 57.2M Q3 '25: 82.3M Q4 '25: 71.2M Q1 '26: 66.1M Q2 '26: -62.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 3M 6M 9M Q2 '26: 8.4M Q2 '26

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -12.5M Q4 '16: -13M Q1 '17: -16.4M Q2 '17: -18.2M Q3 '17: -21M Q4 '17: -22.7M Q1 '18: -20.9M Q2 '18: -24.9M Q3 '18: -27.2M Q4 '18: -39.1M Q1 '19: -50.1M Q2 '19: -56.3M Q3 '19: -65.5M Q4 '19: -62.8M Q1 '20: -61M Q2 '20: -55.2M Q3 '20: -47.7M Q4 '20: -35M Q1 '21: -35.4M Q2 '21: -37.4M Q3 '21: -37M Q4 '21: -65.7M Q1 '22: -65.8M Q2 '22: -63.3M Q3 '22: -59.7M Q4 '22: -43.5M Q1 '23: -41.5M Q2 '23: -42.8M Q3 '23: -41.8M Q4 '23: -37M Q1 '24: -39.8M Q2 '24: -42.2M Q3 '24: -48.7M Q4 '24: -56M Q1 '25: -59.9M Q2 '25: -66M Q3 '25: -74.9M Q4 '25: -76.3M Q1 '26: -77.7M Q2 '26: -76.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '16: -13.3M Q4 '16: -13.5M Q1 '17: -16.7M Q2 '17: -18.5M Q3 '17: -21.2M Q4 '17: -23.5M Q1 '18: -25.2M Q2 '18: -32.6M Q3 '18: -36.5M Q4 '18: -48.4M Q1 '19: -57.1M Q2 '19: -63.9M Q3 '19: -72.4M Q4 '19: -69.1M Q1 '20: -66.5M Q2 '20: -57.3M Q3 '20: -49.1M Q4 '20: -36.4M Q1 '21: -36.7M Q2 '21: -38.2M Q3 '21: -38M Q4 '21: -69.8M Q1 '22: -69.6M Q2 '22: -67M Q3 '22: -63.1M Q4 '22: -43.6M Q1 '23: -41.8M Q2 '23: -43.1M Q3 '23: -42.1M Q4 '23: -37.3M Q1 '24: -40.6M Q2 '24: -43.7M Q3 '24: -50.6M Q4 '24: -58.5M Q1 '25: -63M Q2 '25: -71.3M Q3 '25: -82.4M Q4 '25: -84.3M Q1 '26: -85.2M Q2 '26: -81.5M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '10: 27.9M Q1 '11: 19.2M Q2 '11: 19.4M Q1 '12: 24.1M Q2 '12: 24.2M Q3 '12: 24.2M Q1 '13: 25.2M Q2 '13: 25.5M Q3 '13: 508.7K Q1 '14: 25.9M Q2 '14: 26.2M Q3 '14: 532.3K Q1 '21: 94.2M Q2 '21: 3.9M Q3 '21: 3.9M Q1 '22: 5.8M Q2 '22: 5.8M Q3 '22: 6.4M Q1 '23: 16.9M Q2 '23: 18M Q3 '23: 24.8M Q1 '24: 27.3M Q2 '24: 51.2M Q3 '24: 48.1M Q1 '25: 49.8M Q2 '25: 66.6M Q3 '25: 54.2M Q1 '26: 56.6M Q2 '26: 57M Q2 '10 Q2 '12 Q3 '13 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '13: -0.17 Q2 '13: 0.32 Q4 '15: -0.51 Q1 '16: -0.58 Q2 '16: -0.62 Q3 '16: -0.51 Q4 '16: -0.64 Q1 '17: -0.60 Q2 '17: -0.61 Q3 '17: -0.66 Q4 '17: -0.66 Q1 '18: -0.75 Q2 '18: -0.80 Q3 '18: -1.01 Q4 '18: -1.18 Q1 '19: -1.35 Q2 '19: -1.58 Q3 '19: -1.59 Q4 '19: -1.53 Q1 '20: -1.66 Q2 '20: -1.31 Q3 '20: -1.04 Q4 '20: -0.91 Q1 '21: -0.56 Q3 '22: -3.90 Q4 '22: -5.53 Q1 '23: -2.27 Q2 '23: -4.55 Q3 '23: -4.03 Q4 '23: -2.58 Q1 '24: -3.20 Q2 '24: -2.54 Q3 '24: -2.69 Q4 '24: -2.19 Q1 '25: -1.27 Q2 '25: 0.70 Q3 '25: 1.23 Q4 '25: 1.01 Q1 '26: 0.95 Q2 '26: -1.11 Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.